Cite
PS-100-Bench-to-clinical development of plasminogen as a novel prognostic biomarker for patients with hepatitis B virus related acute-on-chronic liver failure.
MLA
Wu, Daxian, et al. “PS-100-Bench-to-Clinical Development of Plasminogen as a Novel Prognostic Biomarker for Patients with Hepatitis B Virus Related Acute-on-Chronic Liver Failure.” Journal of Hepatology, vol. 70, Apr. 2019, pp. e63–64. EBSCOhost, https://doi.org/10.1016/S0618-8278(19)30112-4.
APA
Wu, D., sun, zeyu, zhang, sainan, rao, qunfang, Hou, Z., Liu, B., Gao, H., & Li, L. (2019). PS-100-Bench-to-clinical development of plasminogen as a novel prognostic biomarker for patients with hepatitis B virus related acute-on-chronic liver failure. Journal of Hepatology, 70, e63–e64. https://doi.org/10.1016/S0618-8278(19)30112-4
Chicago
Wu, Daxian, zeyu sun, sainan zhang, qunfang rao, Zhouhua Hou, Bingjie Liu, Hainv Gao, and Lanjuan Li. 2019. “PS-100-Bench-to-Clinical Development of Plasminogen as a Novel Prognostic Biomarker for Patients with Hepatitis B Virus Related Acute-on-Chronic Liver Failure.” Journal of Hepatology 70 (April): e63–64. doi:10.1016/S0618-8278(19)30112-4.